Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

Summary

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 14 September 2016

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 14 September 2016

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 14 September 2016

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.